The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake

References

• Arbeit JM, Brown JM, Chao KSC, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D. 2006. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. International Journal of Radiation Biology 82:699–757.
   PubMedGoogle Scholar
• Ballinger JR. 2001. Imaging hypoxia in tumors. Seminars in Nuclear Medicine 31:321–329.
   PubMedGoogle Scholar
• Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK, Brady F, Workman P, Price PM, Aboagye EO. 2004. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. British Journal of Cancer 90:2232–2242.
   PubMed Web of Science ®Google Scholar
• Beck R, Roper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke M, Picchio M, Souvatzoglou M, Machulla H-J, Piert M. 2007. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. Journal of Nuclear Medicine 48:973–980.
   PubMed Web of Science ®Google Scholar
• Bergman J, Solin O. 1997. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nuclear Medicine and Biology 24:677–683.
   PubMed Web of Science ®Google Scholar
• Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. 1996. Tissue oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Research 56:941–943.
   PubMed Web of Science ®Google Scholar
• Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ. 2001. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. International Journal Radiation Oncology Biology Physics 49:1171–1182.
   PubMed Web of Science ®Google Scholar
• Chapman JD, Franko AJ, Koch CJ. 1983. The fraction of hypoxic clonogenic cells in tumor populations. In: Fletcher GH, Nervi C, Withers HR, editors. Biological bases and clinical implications of tumor radioresistance. New York: Masson Publishing. pp. 61–73.
   Google Scholar
• Chapman JD, Zanzonico P, Ling CC. 2001. On measuring of hypoxia in individual tumors with radiolabeled agents. Journal of Nuclear Medicine 42:653–655.
   Google Scholar
• Coleman CN, Halsey J, Cox RS, Hirst K, Blaschke T, Howes AE, Wasserman TH, Urtasun RC, Pajek T, Hancock S, Phillips TL, Noll L. 1987. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. Cancer Research 47:319–322.
   PubMedGoogle Scholar
• Coleman CN, Urtasun RC, Wasserman TH, Hancock S, Harris JW, Halsey J, Hirst VK. 1984. Initial report of the Phase I trial of the hypoxic cell radiosensitizer SR-2508. International Journal Radiation Oncology Biology Physics 10:1749–1753.
   PubMed Web of Science ®Google Scholar
• Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. 2003. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response – a preliminary report. International Journal Radiation Oncology Biology Physics 55:1233–1238.
   PubMed Web of Science ®Google Scholar
• Dolbier WR, Li A-R, Koch CJ, Shiue C-Y, Kachur AV. 2001. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Journal of Applied Radiation and Isotopes 54:73–80.
   PubMed Web of Science ®Google Scholar
• Dubois L, Landuyt W, Haustermans K, Dupont P, Bormans G, Vermaelen P, Flamen P, Verbeken E, Mortelmans L. 2004. Evaluation of hypoxia in an experimental rat tumor model by [18F]fluoromisonidazole PET and immunohistochemistry. British Journal of Cancer 91:1947–1954.
   PubMed Web of Science ®Google Scholar
• Eschmann S-M, Paulsen F, Reimold M, Dittmann H, Welz S, Reischi G, Machulla H-J, Bares R. 2005. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. Journal of Nuclear Medicine 46:253–260.
   PubMed Web of Science ®Google Scholar
• Evans SM, Hahn S, Pook DR, Zhang PJ, Jenkins WT, Fraker D, Hsi RA, McKenna WG, Koch CJ. 2000. Hypoxia in human intraperitoneal and extremity sarcomas. International Journal Radiation Oncology Biology Physics 49:587–596.
   Google Scholar
• Evans SM, Jenkins KW, Jenkins WT, Dilling T, Judy KD, Schrlau A, Judkins A, Hahn SM, Koch CJ. 2008. Imaging and analytical methods for the evaluation of vasculature and hypoxia in human brain tumors. Radiation Research 170:677–690.
   PubMed Web of Science ®Google Scholar
• Evans SM, Koch CJ. 2003. Prognostic significance of tumor oxygenation in humans. Cancer Letters 195:1–16.
   PubMedGoogle Scholar
• Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 1996. 2-nitroimidazole (EF5) binding predicts radiation sensitivity in individual 9L subcutaneous tumors. Cancer Research 56:405–411.
   PubMed Web of Science ®Google Scholar
• Flynn RT, Bowen SR, Bentzen SM, Mackie TR, Jeraj R. 2008. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Physics in Medicine and Biology 53:4153–4167.
   PubMed Web of Science ®Google Scholar
• Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Chapman W, Levin W, Manchul L, Keane TJ, Hill RP. 1998. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiotherapy and Oncology 48:149–156.
   PubMed Web of Science ®Google Scholar
• Gronroos T, Bentzen L, Marjamaki P, Murata R, Horsman MR, Keiding S, Eskola O, Haaparanta M, Minn H, Solin O. 2004. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. European Jornal of Nuclear Medicine and Molecular Imaging 31:513–520.
   PubMedGoogle Scholar
• Groshar D, McEwan AJ, Parliament MB, Urtasun RC, Golberg LE, Hoskinson M, Mercer JR, Mannan RH, Wiebe LI, Chapman JD. 1993. Imaging tumor hypoxia and tumor perfusion. Journal of Nuclear Medicine 34:885–888.
   PubMed Web of Science ®Google Scholar
• Grosu A-L, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, Hans-Jurgen W, Reischl. GnHans-Juergen M, Schwaiger M, Molls M, Piert M. 2007. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. International Journal Radiation Oncology Biology Physics 69:541–551.
   PubMed Web of Science ®Google Scholar
• Hockel M, Knoop C, Schlenger K, Vordran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P. 1993. Intratumor pO2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology 26:45–50.
   PubMed Web of Science ®Google Scholar
• Horan A-M, Koch CJ. 2001. The Km for radiosensitization by oxygen is much greater than 3 mm of Hg and is further increased by elevated levels of cysteine. Radiation Research 156:388–398.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Khalil AA, Nordsmark M, Grau C, Overgaard J. 1993. Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model. Radiotherapy and Oncology 28:69–71.
   PubMed Web of Science ®Google Scholar
• Iyer RV, Haynes PT, Schneider RF, Movsas B, Chapman JD. 2001. Marking hypoxia in rat prostate carcinomas with b-D-[125I] Azomycin galactopyranoside and [99mTc]HL-91: Correlation with microelectrode measurements. Journal of Nuclear Medicine 42:337–344.
   PubMedGoogle Scholar
• Jenkins WT, Evans SM, Koch CJ. 2000. Hypoxia and necrosis in rat (L glioma and Morris 7777 hepatoma tumors: Comparative measurements using EF5 binding and Eppendorf needle electrode. International Journal Radiation Oncology Biology Physics 46:1005–1017.
   PubMedGoogle Scholar
• Karp JS, Surti S, Freifelder R, Daube-Witherspoon ME, Cardi C, Adam LE, Muehllehner G. 2003. Performance of a brain PET camera based on Anger-Logic GSO detectors. Journal of Nuclear Medicine 44:1340–1349.
   PubMedGoogle Scholar
• Kavanagh MC, Tsang V, Chow S, Koch C, Hedley D, Minkin S, Hill RP. 1999. A comparison in individual murine tumors of techniques for measuring oxygen levels. International Journal Radiation Oncology Biology Physics 44:1137–1146.
   PubMedGoogle Scholar
• Koch CJ. 1983. Competition between radiation protectors and radiation sensitizers in mammalian cells. In: Nygaard OF, Simic MG, editors. Radioprotectors and anticarcinogens. New York: Academic Press. pp. 275–296.
   Google Scholar
• Koch CJ. 1990. The reductive activation of nitroimidazoles; modification by oxygen and other redox-active molecules in cellular systems. In: Adams GE, Breccia A, Fielden EM, Wardman P, editors. Selective activation of drugs by redox processes. NATO Series. New York: Plenum Press. pp. 237–247.
   Google Scholar
• Koch CJ. 2002. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and the 2-nitroimidazole EF5. In: Sen CK, Packer L, editors. Methods in enzymology – Antioxidants and redox cycling. San Diego: Academic Press. 353:3–31.
   Google Scholar
• Koch CJ. 2008. Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole. Radiation Research 169:677–688.
   PubMedGoogle Scholar
• Koch CJ, Evans SM. 1996. Cysteine concentrations in rodent tumors: unexpectedly high values may cause therapy resistance. International Journal of Cancer 67:661–667.
   PubMed Web of Science ®Google Scholar
• Koch CJ, Evans SM, Lord EM. 1995. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoroproply)acetamide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity. British Jornal of Cancer 72:869–874.
   PubMed Web of Science ®Google Scholar
• Koch CJ, Hahn SM, Rockwell KJ, Covey JM, McKenna WK, Evans SM. 2001. Pharmacokinetics of the 2-Nitroimidazole EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] in Human Patients: Implications for Hypoxia Measurements In Vivo. Cancer Chemotherapy and Pharmacology 48:177–187.
   PubMedGoogle Scholar
• Koh W-J, Rasey JS, Evans ML, Grierson JR, Lewellan TK, Graham MM, Krohn KA, Griffin TW. 1991. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. International Journal Radiation Oncology Biology Physics 22:199–212.
   Web of Science ®Google Scholar
• Komar G, Seppänen, Eskola O, Lindholm P, Grönroos JT, Forsback S, Sipilä H, Evans SM, Solin O, Minn H. 2008. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer. Journal of Nuclear Medicine 49:1–8.
   PubMedGoogle Scholar
• Krohn KA, Link JM, Mason RP. 2008. Molecular imaging of hypoxia. Journal of Nuclear Medicine 49:129S–148S.
   Web of Science ®Google Scholar
• Lee J, Siemann DW, Koch CJ, Lord EM. 1996. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. International Journal of Cancer 67:372–378.
   PubMed Web of Science ®Google Scholar
• Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. 1999. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. Journal of Nuclear Medicine 40:177–183.
   PubMed Web of Science ®Google Scholar
• Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. 2000. Tumor uptake of copper-diacetyl-bis(N4-methylthiosemicarbazone): Effect of changes in tissue oxygenation. Journal of Nuclear Medicine 42:655–661.
   Google Scholar
• Lord EM, Harwell LW, Koch CJ. 1993. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Research 53:5271–5276.
   Google Scholar
• Moulder JE, Rockwell SC. 1984. Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis and a survey of existing data. International Journal Radiation Oncology Biology Physics 10:695–712.
   PubMedGoogle Scholar
• Nickles RJ, Daube ME, Ruth TJ. 1984. An 18O2 target for the production of [18F]F2. International Journal Applied Radiation Isotopes 35:117–122.
   Google Scholar
• Nordsmark M, Overgaard M, Overgaard J. 1996. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 41:31–39.
   PubMed Web of Science ®Google Scholar
• O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL. 2005. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, pO2 probe measurment, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. International Journal Radiation Oncology Biology Physics 61:1493–1502.
   PubMed Web of Science ®Google Scholar
• Otonkoski T, Nanto-Salonen N, Seppanen M, Veijola R, Huopio H, Hussain K, Tapanainen P, Eskola O, Parkkola R, Ekstrom K, Guiot Y, Rahier J, Laakso M, Rintala R, Nuutila P, Minn H. 2006. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA Positron Emission Tomography. Diabetes 55:13–18.
   PubMed Web of Science ®Google Scholar
• Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, Grierson JR, Krohn KA. 2006. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clinical Cancer Research 12:5435–5441.
   PubMed Web of Science ®Google Scholar
• Rasey JS, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK. 2000. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiation Research 153:84–92.
   PubMedGoogle Scholar
• Ribeiro M-J, De Lonlay P, Delzescaux T, Boddaert N, Jaubert F, Bourgeois S, Dolle F, Nihoul-Fekete C, Syrota A, Brunelle F. 2005. Characterization of hyperinsulinism in infancy assessed with PET and 18F-Fluoro-L-DOPA. Journal of Nuclear Medicine 46:560–566.
   PubMed Web of Science ®Google Scholar
• Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S. 2006. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of trans-Tasman Radiation Oncology Group Study 98.02. Journal of Clinical Oncology 24:2098–2104.
   PubMed Web of Science ®Google Scholar
• Saitoh J-I, Sakuri H, Suzuki Y, Muramatsu H, Ishikawa H, Kitamoto Y, Akimoto T, Hasegawa M, Mitsuhashi N, Nakano T. 2002. Correlations between in vivo tumor weight, oxygen pressure, 31P NMR spectroscopy, hypoxic microenvironment marking by b-D-iodinated azomycin galactopyranoside (b-D-IAZGP), and radiation sensitivity. International Journal Radiation Oncology Biology Physics 54:903–909.
   PubMed Web of Science ®Google Scholar
• Siim BG, Menke DR, Dorie MJ, Brown JM. 1997. Tirapazamine-induced cytotoxicity and DNA damage in trasplanted tumors: relationship to tumor hypoxia. Cancer Research 57:2922–2928.
   PubMed Web of Science ®Google Scholar
• Solomon B, Binns D, Roselt P, Weibe LI, McArthur GA, Cullinane C, Hicks RJ. 2005. Modulation of intratumoral hypoxia by the epidermal growth factor receptor unhibitor gefitinib detected using small animal PET imaging. Molecular Cancer Therapeutics 4:1417–1422.
   PubMedGoogle Scholar
• Southwick PL, Ernst LA, Tauriello EW, Parker SR, Mujumdar RB, Mujumdar SR, Clever HA, Waggoner AS. 1990. Cyanine dye labeling reagents – carboxymethylindocyanine succinimidyl esters. Cytometry 11:418–430.
   PubMedGoogle Scholar
• Surti S, Karp JS, Perkins AE, Cardi CA, Daube-Witherspoon ME, Kuhn A, Muehllehner G. 2005. Imaging performance of A-PET: A small animal PET camera. IEEE Transactions Medical Imaging 24:844–852.
   PubMedGoogle Scholar
• Thorwarth D, Eschmann S-M, Scheiderbaur J, Paulsen F, Alber M. 2005. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BioMed Central Cancer 5:152–162.
   Google Scholar
• Thorwarth D, Soukup M, Alber M. 2008. Dose painting with IMPT, helical tomography and IMXT: A dosimetric comparison. Radiotherapy and Oncology 86:30–34.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A. 2007. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer and Metastasis Reviews 26:225–239.
   PubMed Web of Science ®Google Scholar
• Wallen CA, Michaelson SM, Wheeler KT. 1980. Evidence for an unconventional radiosensitivity of rat 9L subcutaneous tumors. Radiation Research 85:529–541.
   Google Scholar
• Workman P. 1980. Pharmacokinetics of hypoxic cell radiosensitizers. Cancer Clinical Trials 3:237–251.
   PubMedGoogle Scholar
• Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. 2006. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacety-bis(N4-methylthiosemicarbaxone). Journal of Nuclear Medicine 47:989–998.
   PubMed Web of Science ®Google Scholar
• Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, Karp JS, Alavi A, Dolbier WR, Koch CJ. 2003. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. European Journal of Nuclear Medicine 30:259–266.
   Google Scholar